- Home
- EPIX
EPIX
ESSA Pharma Inc.
as 11-15-2024 4:00pm EST
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
| Founded: | 2009 | Country: | Canada |
| Employees: | N/A | City: | VANCOUVER |
| Market Cap: | 209.4M | IPO Year: | N/A |
| Target Price: | $9.50 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.40 - $11.67 | Next Earning Date: | 12-10-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of ESSA Pharma Inc. (EPIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BIOTECH GROWTH N V | EPIX | 10% Owner | Nov 1 '24 | Sell | $1.53 | 7,879,583 | $12,018,409.08 | 0 | |
| Virsik Peter | EPIX | Chief Operating Officer | Oct 7 '24 | Sell | $6.03 | 694 | $4,184.82 | 7,776 | |
| Virsik Peter | EPIX | Chief Operating Officer | Sep 9 '24 | Sell | $6.00 | 694 | $4,164.00 | 7,776 | |
| Virsik Peter | EPIX | Chief Operating Officer | Sep 3 '24 | Sell | $6.03 | 2,082 | $12,554.46 | 7,776 |
Latest ESSA Pharma Inc. News
EPIX Breaking Stock News: Dive into EPIX Ticker-Specific Updates for Smart Investing
Simply Wall St.
7 days ago
ESSA Pharma And 2 Other US Penny Stocks To Watch
Argus Research
11 days ago
Daily – Vickers Top Buyers & Sellers for 11/06/2024
Investing.com
13 days ago
ESSA Pharma downgraded by Oppenheimer, Piper Sandler after drug setback in trials
MT Newswires
16 days ago
Sector Update: Health Care Stocks Rise Late Afternoon
MT Newswires
16 days ago
Top Midday Decliners
MT Newswires
16 days ago
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday
MT Newswires
16 days ago
Top Premarket Decliners
Clinical Trials Arena
16 days ago
ESSA Pharma halts Phase II study of masofaniten in prostate cancer treatment
Compare EPIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EPIX ESSA Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.